New technique of local ischemic preconditioning induction without repetitive aortic cross-clamping in cardiac surgery

Dmitry I Kurapeev¹, Viktor O Kabanov², Vadim K Grebennik², Tatyana A Sheshurina², Vladimir V Dorofeykov², Michael M Galagudza¹,³* and Eugene V Shlyakhto²

Abstract

Background: Several studies have demonstrated that local ischemic preconditioning can reduce myocardial ischemia–reperfusion injury in cardiac surgery patients; however, preconditioning has not become a standard cardioprotective intervention, primarily because of the increased risk of atheroembolism during repetitive aortic cross-clamping. In the present study, we aimed to describe and validate a novel technique of preconditioning induction.

Methods: Patients undergoing coronary artery bypass grafting (12 women and 78 men; mean age, 56 ± 11 years) were randomized into 3 groups: (1) Controls (n = 30), (2) Perfusion (n = 30), and (3) Preconditioning (n = 30). All patients were operated under cardiopulmonary bypass using normothermic blood cardioplegia. Preconditioning was induced by subjecting the hemodynamically unloaded heart to 2 cycles of 3 min of ischemia and 3 min of reperfusion with normokalemic blood prior to cardioplegia. In the Perfusion group, the heart perfusion remained unaffected for 12 min. Troponin I (TnI) levels were analyzed before surgery, and 12, 24, 48 h, and 7 days after surgery. The secondary endpoints included the cardiac index, plasma natriuretic peptide level, and postoperative use of inotropes.

Results: Preconditioning resulted in a significant reduction in the TnI level on the 7th postoperative day only (0.10 ± 0.05 and 0.33 ± 0.88 ng/ml in Preconditioning and Perfusion groups, respectively, P < 0.05). In addition, cardiac index was significantly higher in the Preconditioning group than in the Control and Perfusion groups just after weaning from cardiopulmonary bypass. The number of patients requiring inotropic support with ≥ 2 agents after surgery was significantly lower in the Preconditioning and Perfusion group than in the Control group (P < 0.05). No complications of the procedure were recorded in the Preconditioning group.

Conclusions: The preconditioning procedure described can be performed safely in cardiac surgery patients. The application of this technique of preconditioning was associated with certain benefits, including improved left ventricular function after weaning from cardiopulmonary bypass and a reduced need for inotropic support. However, the infarct-limiting effect of preconditioning in the early postoperative period was not evident. The procedure does not involve repetitive aortic cross-clamping, thus avoiding possible embolic complications.

Keywords: Local ischemic Preconditioning, Myocardial ischemia–reperfusion, Cardioplegia, Cardiopulmonary bypass, Troponin I, Cardiac index

* Correspondence: galagoudza@mail.ru
¹Institute of Experimental Medicine, Federal Almazov Medical Research Centre, Saint Petersburg, Russian Federation
²Department of Pathophysiology, First I.P. Pavlov Federal Medical University of St. Petersburg, Saint Petersburg, Russian Federation
³Department of Pathophysiology, First I.P. Pavlov Federal Medical University of St. Petersburg, Saint Petersburg, Russian Federation

© 2015 Kurapeev et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Although the number of open heart surgeries performed each year has declined in the past decade, the proportion of very elderly patients with multiple comorbidities and/or multivessel coronary artery disease (CAD) undergoing major heart surgery is continuously increasing [1]. The peri- and postoperative mortality and morbidity has been reported to be increased in this patient population [2,3], which may be attributed—at least in part—to suboptimal myocardial protection due to a longer duration of aortic cross-clamping in advanced CAD [4], as well as the enhanced susceptibility of the aged and diabetic myocardium to ischemia–reperfusion injury (IRI) [5,6]. Therefore, the development and application of new cardioprotective approaches in cardiac surgery remains important.

Increased myocardial tolerance to IRI after a single episode or several brief episodes of ischemia–reperfusion is referred to as local ischemic preconditioning (IP) [7]. A large body of experimental evidence suggests that IP represents one of the most effective endogenous cardioprotective interventions developed thus far [8,9]. The predictability of ischemia onset and direct access to the heart are 2 major prerequisites for the successful clinical use of IP, both of which are fulfilled during open heart operations with cardiopulmonary bypass (CPB). At present, the cardioprotective effectiveness of IP in cardiac surgery patients has been demonstrated in several small clinical trials. In particular, IP has been shown to reduce the postoperative levels of cardiac troponins [10] and to improve left and right ventricular contractile function [11,12]. In addition, the beneficial effects of IP on certain clinical endpoints, such as the incidence of ventricular arrhythmias [13], inotrope requirements [14], and intensive care unit (ICU) stay [15], have been clearly demonstrated. In all these studies, IP was induced after the initiation of CPB by 1 or 2 brief (1–5 min) cycles of aortic clamping followed by reperfusion prior to cardioplygeic arrest. Although this protocol of IP induction seems to be safe in pediatric patients with congenital heart defects [16], repetitive aortic cross-clamping might be associated with an increased risk of atheroembolism in adult patients with diffuse atherosclerosis undergoing coronary artery bypass graft (CABG) surgery [17]. Thus, the development of alternative techniques of IP induction without repetitive (de)clamping of the ascending aorta is important.

In the present study, we describe a new technique of IP induction that does not require repeated aortic cross-clamping in patients undergoing cardiac surgery. In addition, we assessed the effects of the modified IP technique on serum cardiac troponin I (cTnI) and brain natriuretic peptide (BNP) levels, cardiac index (CI), left ventricular function, and clinical parameters in CABG patients.

Methods

This single-center, double-blinded, randomized controlled study conforms to the principles outlined in the Declaration of Helsinki and UCL Good Clinical Practice Guidelines. The study design was approved by the ethics committees at Federal Almazov Medical Research Centre, St Petersburg, Russian Federation. Written informed consent was obtained from each patient before the operation.

Inclusion/exclusion criteria

From March 2010 to October 2013, 90 patients (12 women and 78 men; mean age, 56 ± 11 [standard deviation] years) with 3-vessel CAD admitted for elective CABG surgery were enrolled in the prospective study. Patients with severe non-coronary cardiac disease, left ventricular ejection fraction < 50%, unstable angina, or history of myocardial infarction within 3 months prior to surgery were excluded. Patients with diabetes mellitus and those receiving inotropic agents prior to CPB were also excluded.

Anesthesia and surgical technique

Premedication consisted of oral benzodiazepines and intramuscular morphine (0.15 mg/kg) given 1.5 h preoperatively. Before anesthesia, the right radial artery was cannulated and a Swan–Ganz pulmonary artery catheter was introduced through the right jugular vein. The patients were anesthetized by intravenous infusion of fentanyl and propofol. Pipecuronium bromide (0.15 mg/kg) was used for muscle relaxation. The activated clotting time was maintained at >450 s. CPB was established with a single 2-stage venous cannula and ascending aortic cannula. During CPB, the core body temperature was maintained at 36.0°C ± 0.5°C. The pump volume flow rate was 2.4–2.6 L/min/m², and mean arterial pressure was maintained between 60 and 80 mm Hg. Intraoperative protection of the heart was performed using intermittent anteretrograde warm blood cardioplegia. Antegrade cardioplegia was performed through the cannula positioned in the aortic root. Left ventricular venting was accomplished in all patients through the right superior pulmonary vein. The coronary sinus was cannulated with a self-inflating cannula for retrograde cardioplegia delivery. The ascending aorta was cross-clamped above the origin of the coronary arteries, followed by the ante-retrograde cardioplegia using a blood-based cardioplegia solution containing 20 mmol/L of potassium chloride. Oxygenated blood for cardioplegia was taken via the special outlet port of the oxygenator and delivered into the aortic cannula or coronary sinus using peristaltic pump. Before entering the vessels, the blood was supplemented with 10% solution of potassium chloride (KCl) via T-connector using the syringe pump. The volume flow rate of blood-based cardioplegia was kept at 200 ml/min during both induction of cardioplegia and maintenance of cardioplegic arrest (Table 1). The first
Table 1 Protocol of intermittent ante-retrograde warm blood cardioplegia

| Episode of cardioplegia (No) and mode of infusion | Volume flow rate of blood delivery (ml/min) | Volume flow rate of delivery of 10% KCl solution (ml/h) | Duration of cardioplegia infusion (min) |
|-------------------------------------------------|---------------------------------------------|----------------------------------------------------------|----------------------------------------|
| 1 - antegrade*                                   | 200                                         | 100 (preceded by bolus dose of 4 ml)                      | 2.5                                    |
| 1 - retrograde                                   | 200                                         | 10                                                       | 3.0                                    |
| 2 - retrograde                                   | 200                                         | 10 (preceded by bolus dose of 2 ml)                       | 3.0                                    |
| 3 - retrograde                                   | 200                                         | 10                                                       | 3.0                                    |
| 4 - retrograde                                   | 200                                         | 10                                                       | 4.0                                    |
| 5 - retrograde                                   | 200                                         | 10                                                       | 5.0                                    |

*First episode of cardioplegia consisted of 2.5-min antegrade infusion plus 3.0-min retrograde infusion.

An episode of cardioplegia consisted of 2.5-min period of antegrade heart perfusion followed by 3.0-min period of retrograde perfusion. The beginning of antegrade delivery of blood was accompanied by bolus injection of 4 ml 10% KCl in the cardioplegia line followed by its infusion at a rate of 100 ml/h. During retrograde delivery of blood, the rate of KCl solution infusion was 10 ml/h. The blood cardioplegia solution containing 8 mmol/L of potassium chloride was infused for maintenance of cardiac arrest with an interval of approximately 15 min. The decrease in potassium concentration in the final cardioplegic solution was partially compensated by longer durations of subsequent (4th and 5th) episodes of cardioplegia (Table 1). The rationale for decreasing potassium concentration was to avoid hyperkalemia-induced myocardial injury and accelerate recovery of myocardial contractility during reperfusion.

The pressure in the coronary sinus was monitored throughout the procedure and was kept below 60 mm Hg. During antegrade cardioplegia, the pressure in the ascending aorta was monitored by the manometer and manual inspection of the aorta was performed to verify aortic valve closure.

Infusion of vasopressor (mesatone) was used in the patients with systemic vascular resistance of less than 800 dynes/s/cm². Epinephrine, norepinephrine, and dopamine were used for inotropic support. Patients received inotropes either based on the observation of reduced cardiac contractility during and after weaning from CPB (by direct visual inspection of the right ventricle and/or transesophageal echocardiography) or after measuring a reduced CI (<2.0 L/min/m²), or both.

Preconditioning protocol

All patients were randomized into one of the following 3 groups: (1) Control (n = 30); (2) Perfusion (n = 30); and (3) IP (n = 30). Randomization was performed in the surgery room; a sealed, nontransparent protocol envelope was opened for each patient and the patient was accordingly assigned to a group. The Control group included patients undergoing conventional CABG surgery. In the Perfusion group, a 12-min period of CPB was instituted before the application of the aortic cross-clamp in order to account for the effect of additional CPB time required for IP induction on the outcomes. In the IP group, preconditioning was elicited by cross-clamping the aorta and leaving the hemodynamically unloaded heart in the ischemic state for 3 min. During preconditioning ischemia, the left vent was run at 50 ml/min. A 3-min episode of ischemia was followed by 3 min of reperfusion with normokalemic blood delivered in the aortic root at a rate of 300 ml/min. The second episode of 3 min of ischemia was initiated by the cessation of re(perfusion) through the antegrade cardioplegia cannula. The full IP protocol included 2 cycles of 3 min of ischemia plus 3 min of reperfusion. The second 3-min episode of reperfusion was followed by the initiation of standard ante-retrograde blood cardioplegia.

Measurements

The primary endpoint of the study was postoperative cTnI release. Blood samples for cTnI determination were obtained from each patient before the institution of CPB as well as 2, 6, 12, 24, and 48 h after surgery. Additional blood sampling was performed 7 days after surgery. BNP levels were determined preoperatively as well as on the 1st and 7th postoperative day. Serum levels of cTnI and BNP were measured using a chemiluminescent immunoassay (Architect i2000SR, Abbott Diagnostics, USA).

Left ventricular ejection fraction, left ventricular end-systolic volume, left ventricular end-diastolic volume, and left ventricular end-systolic and end-diastolic diameters were measured using echocardiography before surgery and on the 7th postoperative day. The cardiac index (CI) was calculated using the following formula: CI = cardiac output (l/min)/body surface area (m²). CI was calculated in all patients at 5 time points: (1) baseline (before induction of anesthesia); (2) prior to CPB; (3) after weaning from CPB; (4) 12 h after surgery; and (5) 24 h after surgery.

The duration of mechanical ventilation and length of stay in the ICU were recorded. The number of patients requiring inotropic support with ≥2 agents, mean number of inotropic drugs used, and mean total duration of inotrope use (h) were also recorded. The physicians in
ICU and Echo lab were blinded to the group assignments. Postoperative morbidity and mortality on day 20 after the operation were recorded.

Statistical analysis
Statistical analysis was performed using the SPSS 12.0 software package. All data in the text are expressed as mean ± standard deviation (SD). The sample size per group was determined using the following parameters: SD values calculated on the basis of previous studies, desired confidence level (95%), and acceptable difference in outcome between the groups (Statistics Calculator). The Kruskal–Wallis test was used to determine differences in the parameters analysed, followed by pairwise inter-group comparisons at each time point performed using non-parametric Mann–Whitney U tests. Fisher’s exact test was used to determine whether there were any differences between the groups in the number of patients requiring inotropic support with ≥2 agents. P values of ≤0.05 were considered significant.

Results
Perioperative characteristics of the patients
The preoperative data of the patients were similar between the 3 groups. There were no significant differences in age, sex, New York Heart Association class, previous myocardial infarction, and comorbidities such as peripheral vascular disease and chronic obstructive pulmonary disease among the groups. The CPB time, aortic cross-clamping time, total duration of cardioplegia infusion, number of distal anastomoses and duration of mechanical ventilation were also similar among the groups (Table 2).

cTnI and BNP levels
According to the manufacturer’s recommendations, the 99th percentile reference cutoff for the cTnI level was 0.3 ng/mL. Prior to surgery, cTnI levels were well below the upper reference limit in all groups (Table 3). The maximum release of cTnI was observed between 6 and 24 h after surgery, followed by a progressive decrease in concentration. There were no differences in cTnI levels between the groups except for the cTnI level at the 7th postoperative day, which was significantly lower in the IP group than in the Perfusion group (P < 0.05, Table 3). The pre- and postoperative serum BNP levels are presented in Table 4. Although surgery resulted in significant elevation of BNP concentration, the BNP levels did not differ between the groups at any time point.

Left ventricular function
The pre- and postoperative echocardiographic parameters of left ventricular function did not differ among the groups (Table 5). The preoperative values of CI also did not differ among groups (Table 6). CI tended to decrease after induction of anesthesia and increased after weaning from CPB. Immediately after weaning from CPB, the CI was significantly higher in the IP group compared with the Control and Perfusion groups (P < 0.01, Table 6). At 12 and 24 h after surgery, the CI was lower in the Perfusion group than in the Control group (P < 0.05). IP resulted in a significantly higher CI at 24 h after surgery compared with that in the Perfusion group (P < 0.05).

Postoperative course and inotrope requirement
None of the patients experienced perioperative myocardial infarction or stroke. No complications of the procedure were recorded in the IP group. There was 1 case of resternotomy in the Perfusion group because of persistent

| Table 2 | perioperative characteristics of the patients |
|----------------|---------------------------------|
| Characteristic | Control (n = 30) | Perfusion (n = 30) | IP (n = 30) |
| Age (years) | 55.4 ± 5.2 | 57.3 ± 5.6 | 56.6 ± 4.3 |
| Gender (male/female) | 5/25 | 3/27 | 4/26 |
| Previous myocardial infarction | 18 (60%) | 20 (67%) | 18 (60%) |
| NYHA class II | 21 (70%) | 22 (73%) | 23 (77%) |
| NYHA class III | 9 (30%) | 8 (27%) | 7 (23%) |
| COPD | 11 (36%) | 10 (33%) | 9 (30%) |
| PAD | 5 (17%) | 6 (20%) | 5 (17%) |
| CPB time (min) | 86 ± 28 | 98 ± 29 | 89 ± 32 |
| Aortic cross-clamping time (min) | 48 ± 16 | 49 ± 19 | 52 ± 23 |
| Total duration of cardioplegia (min) | 9.8 ± 2.5 | 9.8 ± 3.2 | 9.9 ± 3.6 |
| Number of distal anastomoses | 3.2 ± 0.8 | 3.2 ± 0.5 | 3.4 ± 0.7 |
| Graft material (LIMA/saphenous vein/radial artery) (%) | 100/100/13.3 | 100/100/13.3 | 100/100/16.7 |
| Duration of mechanical ventilation (h) | 14 ± 6 | 14 ± 4 | 12 ± 3 |

Data are mean ± standard deviation. COPD – chronic obstructive pulmonary disease; CPB – cardiopulmonary bypass; IP – local ischemic preconditioning; LIMA – left interior mammary artery; NYHA – New York Heart Association; PAD – peripheral arterial disease.

| Table 3 | Pre- and postoperative serum levels of cardiac troponin I (ng/ml) |
|----------------|---------------------------------|
| Time point | Control (n = 30) | Perfusion (n = 30) | IP (n = 30) |
| Before surgery | 0.004 ± 0.008 | 0.005 ± 0.011 | 0.010 ± 0.012 |
| 2 h after surgery | 0.84 ± 0.79 | 1.61 ± 1.68 | 1.18 ± 0.77 |
| 6 h after surgery | 1.48 ± 0.83 | 1.57 ± 0.78 | 1.65 ± 0.98 |
| 12 h after surgery | 1.52 ± 0.62 | 1.57 ± 0.89 | 1.56 ± 0.61 |
| 24 h after surgery | 1.67 ± 1.03 | 1.92 ± 2.45 | 1.17 ± 0.56* |
| 48 h after surgery | 0.97 ± 0.61 | 1.32 ± 1.83 | 0.75 ± 0.42 |
| 7 days after surgery | 0.19 ± 0.23 | 0.33 ± 0.88 | 0.10 ± 0.05* |

Data are mean ± standard deviation. IP – local ischemic preconditioning. *P < 0.05 versus Perfusion.
Table 4 Pre- and postoperative serum levels of brain natriuretic peptide (ng/ml)

| Time point          | Control (n = 30) | Perfusion (n = 30) | IP (n = 30) |
|---------------------|------------------|--------------------|------------|
| Before surgery      | 41.6 ± 25.5      | 33.7 ± 25.1        | 43.8 ± 40.1|
| 24 h after surgery  | 268.2 ± 129.2    | 310.2 ± 210.3      | 267.0 ± 2003|
| 7 days after surgery| 147.5 ± 59.5     | 171.0 ± 98.2       | 160.0 ± 826|

Data are mean ± standard deviation. CPB – cardiopulmonary bypass; IP – local ischemic preconditioning.

Table 5 Pre- and postoperative echocardiographic parameters of left ventricular function

| Time point          | Control (n = 30) | Perfusion (n = 30) | IP (n = 30) |
|---------------------|------------------|--------------------|------------|
| Left ventricular ejection fraction, % | 63.7 ± 6.2      | 63.6 ± 6.3        | 61.6 ± 5.9 |
| 7 days after surgery| 63.0 ± 6.6       | 61.9 ± 7.0        | 62.5 ± 6.7 |
| Left ventricular end-systolic volume, mL | 50.4 ± 15.1      | 49.7 ± 15.1       | 53.3 ± 14.8|
| 7 days after surgery| 48.2 ± 11.9      | 50.8 ± 15.3       | 50.5 ± 14.2|
| Left ventricular end-diastolic volume, mL | 137.3 ± 21.9     | 134.6 ± 22.1      | 137.1 ± 18.7|
| 7 days after surgery| 130.1 ± 13.7     | 130.9 ± 22.5      | 134.0 ± 19.7|
| Left ventricular end-systolic diameter, mm | 35.4 ± 4.2       | 34.5 ± 4.5        | 34.2 ± 3.7 |
| 7 days after surgery| 33.6 ± 3.3       | 34.8 ± 4.1        | 34.3 ± 3.6 |
| Left ventricular end-diastolic diameter, mm | 53.0 ± 3.0       | 52.7 ± 3.7        | 53.2 ± 3.7 |
| 7 days after surgery| 51.9 ± 2.2       | 52.4 ± 3.8        | 52.6 ± 3.2 |

Data are mean ± standard deviation. IP – local ischemic preconditioning.
to the onset of continuous retrograde warm cardioplegia [31]. The negative result of this study might be well attributed to the lack of test (prolonged) myocardial ischemia, whereas the increased level of CK-MB in the IP group reflects the sublethal myocardial injury caused by the preconditioning procedure itself. Kaukoranta et al. [32] noted a trend toward increased levels of CK-MB and cTnT after IP—an observation that could also be explained by the insufficient severity of test ischemia since this study utilized an almost uninterrupted coronary infusion of cardioplegia. The duration of myocardial ischemia was only 9% and 8% of the total cross-clamp time in IP and control groups, respectively. It should be noted, however, that IP failed to limit infarct size in several studies utilizing intermittent cold blood cardioplegia associated with an appreciable duration of test ischemia [33,34]. Nonetheless, these data led to the major conclusion that the limitation of significant infarct size through IP is more likely to be obtained in high-risk patients with the longest aortic cross-clamp times and severe left ventricular hypertrophy [35]. These patients are more likely to sustain significant perioperative myocardial injury during surgery, which might be potentially attenuated by protective maneuvers such as IP. Clinical data also indicate that IP may be especially useful for the preservation of right ventricular function because the right ventricle may be suboptimally protected during ante-retrograde cardioplegia [13].

The protocol for IP is crucial for effective myocardial protection. Experimental studies have indicated that the infarct-limiting effect of IP is generally proportional to the number of brief preconditioning stimuli, whereas the application of a single IP episode results in a marginal protective effect [36]. In this regard, the lack of IP effect on myocardial infarct size in some clinical trials could be, at least in part, attributed to the application of a single preconditioning episode instead of repeated episodes [11,32,37]. To our knowledge, none of the clinical studies on IP effects in cardiac surgery used an IP protocol consisting of >2 episodes of brief ischemia–reperfusion. The likely explanation for this fact is that repetitive aortic cross-clamping and subsequent declamping significantly increases the risk of atheroembolism. It is known that even the standard procedure of aortic cross-clamping in the patients with advanced atherosclerosis of the ascending aorta is associated with microembolism of the brain vessels, resulting in a varying degree of neurocognitive impairment [38,39]. Therefore, it is not surprising that the increased risk of atheroembolism due to repetitive aortic cross-clamping is one of the major factors hindering the routine application of IP in cardiac surgery [17]. Of note, the results of meta-analysis including 22 clinical trials on IP in cardiac surgery (933 patients), showed that IP significantly reduced the incidence of arrhythmias, postoperative inotrope use, and duration of ICU stay, which was corroborated by the results of the present study [40]. The authors speculated that the most rigorous evidence for the protective effect of IP could be obtained if one could demonstrate a twofold decrease in mortality, which, however, would require an inclusion of ≥3800 patients in each arm of the study. The introduction of IP protocols based on the no-touch-to-aorta techniques may facilitate this task.

A further protocol-related factor that plays an important role in the expression of IP-mediated protective phenotype is the ratio between the duration of ischemic and reperfusion phase of preconditioning cycle. Experimental data clearly demonstrate that IP is most effective when the duration of the reperfusion episode is equal to that of the ischemic episode or exceeds it. The indirect evidence supporting the validity of this notion was derived from the results of a recent clinical trial on IP that showed no infarct size limitation after the application of 2 cycles of 2 min of ischemia and 1 min of reperfusion [41].

Several studies have tested the hypothesis that CBP itself may elicit a preconditioning-like response, primarily through the development of a low-grade systemic inflammatory response [42]. Important data supporting this concept were obtained by Ghosh and Galinanes [37], who found a significant cardioprotective effect of IP only in patients undergoing off-pump CABG and not in those subjected to cardioplegia or intermittent cross-clamp fibrillation. Subsequently, IP has been shown to exert a significant protective effect in other studies performed on CABG patients operated off-pump [43,44]. However, it seems that the preconditioning-like effect of CPB may still permit additional protection afforded by IP. This idea is supported by the large body of evidence demonstrating IP-

| Parameter                        | Control (n = 30) | Perfusion (n = 30) | IP (n = 30) |
|----------------------------------|-----------------|-------------------|-------------|
| No of patients treated with ≥2 agents | 8               | 5*                | 4*          |
| Mean number of inotropic drugs   | 0.7 ± 0.8       | 0.5 ± 0.7         | 0.5 ± 0.7   |
| Mean total duration of inotrope use (h) | 8.8 ± 12.1     | 7.6 ± 13.4        | 6.6 ± 8.9   |
| Mean dose of epinephrine (μg/kg/min) | 0.014 ± 0.022   | 0.010 ± 0.019     | 0.008 ± 0.017 |
| Mean dose of norepinephrine (μg/kg/min) | 0.035 ± 0.025   | 0.028 ± 0.036     | 0.051 ± 0.045 |
| Mean dose of dopamine (μg/kg/min)  | 0.75 ± 1.57     | 0.35 ± 1.14       | 0.89 ± 1.83 |

Data are mean ± standard deviation. CPB – cardiopulmonary bypass; IP – local ischemic preconditioning. *P < 0.05 versus Control.
induced limitation of infarct size and amelioration of clinical parameters in the patients undergoing CBP [30,40]. Although BNP measurements are not routinely used in the studies on myocardial protection, the data start to accumulate that BNP measurement might be also relevant for patients undergoing cardiac surgery. It is well established that BNP levels are severely increased after heart transplantation (e.g., [45]) including the patients without severe hemodynamic perturbations or allograft rejection. Postoperative plasma BNP is independent predictor of cardiac dysfunction after cardiac surgery [46]. Therefore, we were interested to see whether BNP can be used as a secondary biochemical marker of myocardial protection. Although we noted significant elevation of BNP at 24 h postoperatively in all groups, there were no inter-group differences.

In conclusion, the present study describes a new technique of IP induction in cardiac surgery patients. This technique does not require repetitive aortic cross-clamping, which makes the preconditioning procedure safe for the patients with advanced atherosclerosis. The application of this technique of IP was associated with certain benefits, including improved left ventricular function after weaning from CPB and a reduced need for inotropic support. However, the infarct-limiting effect of IP in the early postoperative period was not evident—this requires additional refinement of the IP protocol as well as the identification of patient categories that may benefit from the application of IP.

Conclusions
The IP procedure described can be performed safely in cardiac surgery patients. The application of this technique of IP was associated with certain benefits, including improved left ventricular function after weaning from CPB and a reduced need for inotropic support. However, the infarct-limiting effect of IP in the early postoperative period was not evident. The procedure does not involve repetitive aortic cross-clamping, thus avoiding possible embolic complications.

Acknowledgments
This work was supported by the grant of the President of the Russian Federation for support of leading scientific groups 1611:2014:7 (to DIK and MMG).

References
1. Johnson WM, Smith JM, Woods SE, Hendy MP, Hiratzka LF. Cardiac surgery in octogenarians: does age alone influence outcomes? Arch Surg. 2005;140:1089–93.
2. Salazar E, Torres J, Barragan R, Lopez M, Lasses LA. Aortic valve replacement in patients 70 years and older. Clin Cardiol. 2004;27:565–70.
3. Hakala T, Pitkarinen O, Halonen P, Mustonen J, Turpeinen A, Hippelainen M. Early and late outcome after coronary artery bypass surgery in diabetic patients. Scand Cardiovasc J. 2005;39:177–81.
4. Sommerhaug RG, Wolfe SF, Reid DA, Lindsey DE, Prato SJ, Frounkelien LE, et al. Comparative use of cold blood potassium cardioplegia in coronary bypass patients necessitating long (2.5–6 h) versus short (less than 1.5 h) aortic cross-clamp times. Clin Cardiol. 1988;11:690–5.
5. Mariani J, Ou R, Bailey M, Rowland M, Nagle P, Rosenfeldt F, et al. Tolerance to ischemia and hypoxia is reduced in aged human myocardium. J Thorac Cardiovasc Surg. 2000;120:660–7.
6. Alegria JR, Miller TD, Gibbons RJ, Yi QL, Yusuf S. Collaborative Organization of Rheothrix Evaluation (CORE) Trial Investigators. Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy. Am Heart J. 2007;154:743–50.
7. Munty CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124–36.
8. Yellen DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1113–51.
9. Galagudza MM, Blokhin IO, Shmonin AA, Mischenko KA. Reduction of myocardial ischemia-reperfusion injury with pre- and postconditioning: molecular mechanisms and therapeutic targets. Cardiovasc Hematol Disord Drug Targets. 2008;8:467–65.
10. Jenkins DP, Pugsley WB, Alkilualafi AM, Kemp M, Hooper J, Yellen DM. Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery. Heart. 1997;77:314–8.
11. Wu ZK, Tariffa M, Pelkonen E, Kaukinen L, Honkonen EL, Kaukinen S. Ischaemic preconditioning has beneficial effects on left ventricular haemodynamic function after a coronary artery bypass grafting operation. Scand Cardiovasc J. 2000;34:247–53.
12. Wu ZK, Tariffa M, Pelkonen E, Kaukinen L, Honkonen EL, Kaukinen S. Beneficial effects of ischemic preconditioning on right ventricular function after coronary artery bypass grafting. Ann Thorac Surg. 2000;70:1551–7.
13. Wu ZK, Iivanainen T, Pelkonen E, Laurikka J, Tariffa MR. Antiarrhythmic effect of ischemic preconditioning in recent unstable angina patients undergoing coronary artery bypass grafting. World J Surg. 2004;28:74–9.
14. Illes RW, Swoyer KD. Prospective, randomized clinical study of ischemic preconditioning as an adjunct to intermittent cold blood cardioplegia. Ann Thorac Surg. 1998;65:748–52.
15. Li G, Chen S, Lu E, Li Y. Ischemic preconditioning improves preservation with cold blood cardioplegia in valve replacement patients. Eur J Cardiothorac Surg. 1999;15:653–7.
16. Luo WJ. Ischemic preconditioning in children undergoing open heart operation. Ann Thorac Surg. 1998;66:2163–4.
17. Valsecchi D, Alain JA. Pre- and postconditioning during cardiac surgery. Basic Res Cardiol. 2005;100:179–86.
18. Maruyama Y, Chambers DJ. Myocardial protection: efficacy of a novel magnesium-based cardioplegia (RS-C) compared to St Thomas’ Hospital cardioplegic solution. Interact Cardiovasc Thorac Surg. 2008;7:745–9.
19. Minaasian SM, Galagudza MM, Dmitriev YV, Kurapeev DI, Vlasov TD. Myocardial protection against global ischemia with Krebs-Henseleit buffer-based cardioplegic solution. J Cardiothorac Surg. 2013;8:60.
20. Dahlin LG, Olin C, Svedjeholm R. Perioperative myocardial infarction in cardiac surgery–risk factors and consequences: a case control study. Scand Cardiovasc J. 2000;34:522–7.

21. Masse L, Antonacci M. Low cardiac output syndrome: identification and management. Crit Care Nurs Clin North Am. 2019;31:375–83.

22. Westaby S, Balacumarswamy L, Sayeed R. Maximizing survival potential in very high risk cardiac surgery. Heart Fail Clin. 2007;3:159–80.

23. Yellon DM, Alkhulali AM, Pugsley WB. Preconditioning the human myocardium. Lancet. 1993;342:276–7.

24. Teoh LK, Grant R, Huff JA, Pugsley WB, Yellon DM. A comparison between ischemic preconditioning, intermittent cross-clamp fibrillation and cold crystalloid cardioplegia for myocardial protection during coronary artery bypass graft surgery. Cardiovasc Surg. 2002;10:251–5.

25. Lu EX, Chen SX, Yuan MD, Hu TH, Zhou HC, Luo WJ, et al. Preconditioning improves myocardial preservation in patients undergoing open heart operations. Ann Thorac Surg. 1997;64:1320–4.

26. Buyukates M, Kalaycioglu S, Oz E, Soncül H. Effects of ischemic preconditioning in human heart. J Card Surg. 2005;20:241–5.

27. Szmagala P, Morawski W, Krejca M, Oburek T, Bochenek A. Evaluation of perioperative myocardial tissue damage in ischemically preconditioned human heart during aorto coronary bypass surgery. J Cardiovasc Surg (Torino). 1998;39:791–5.

28. Ji B, Liu M, Liu J, Wang G, Feng W, Lu F, et al. Evaluation by cardiac troponin I: the effect of ischemic preconditioning as an adjunct to intermittent blood cardioplegia on coronary artery bypass grafting. Card Surg. 2007;22:394–400.

29. Wu ZK, Iivainen T, Pehkonen E, Laurikka J, Tartika MR. Ischemic preconditioning suppresses ventricular tachyarrhythmias after myocardial revascularization. Circulation. 2002;106:3091–6.

30. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet. 2013;381:166–75.

31. Perrault LP, Menasche P, Bel A, De Chaumaray T, Peynet J, Mondry A, et al. The effects of ischemic preconditioning with a short reperfusion phase on patients undergoing a coronary artery bypass graft. Ann Thorac Cardiovasc Surg. 2008;34:985–90.

32. Kaukoranta PK, Lepojarvi MV, Kiviluoma KT, Ylitalo KV, Peuhkurinen KJ. Regional ischemic preconditioning enhances myocardial performance in off-pump coronary artery bypass grafting. Chest. 2002;121:1183–99.

33. Talha S, Charloux A, Enache I, Piiparit E, Gency B. Mechanisms involved in increased plasma brain natriuretic peptide after heart transplantation. Cardiovasc Res. 2011;89:273–81.

34. Provenchère S, Berroeta C, Reynaud C, Baron G, Poirier I, Desmonts JM, et al. Plasma brain natriuretic peptide and cardiac troponin I concentrations after adult cardiac surgery: association with postoperative cardiac dysfunction and 1-year mortality. Crit Care Med. 2006;34:995–1000.

35. Hausenloy DJ, Baxter G, Bell R, Botker HE, Davidson SM, Downey J, et al. Preconditioning during cardiac surgery: a word of caution. J Thorac Cardiovasc Surg. 1998;116:1378–86.

36. Cremer J, Steinhoff G, Karck M, Ahnsell T, Brandt M, Teebken OE, et al. Evidence for improved cerebral function after minimally invasive cardiac surgery. J Thorac Cardiovasc Surg. 2000;119:233–42.

37. BhaskerRao B, VanHlimbergen D, Edmunds JH, Jaber S, Ali AT, Pagni S, et al. Particulate emboli capture by an intra-aortic filter device during cardiac surgery. J Thorac Cardiovasc Surg. 2000;119:333–41.

38. Walsh SR, Tang TY, Kullar P, Jenkins DP, Dutka DP, Gaunt ME. Ischaemic preconditioning during cardiac surgery: systematic review and meta-analysis of periprocedural outcomes in randomised clinical trials. Eur J Cardiothorac Surg. 2009;34:985–94.

39. Jelbić M, Esmaili HR, Mandegar MH, Rasouli MR, Eghtesadi-Araghi P, Mohammadzadeh R, et al. Evaluation of the effects of ischemic preconditioning with a short reperfusion phase on patients undergoing a coronary artery bypass graft. Ann Thorac Cardiovasc Surg. 2010;16:248–52.

40. Burns PG, Krukenkamp B, Calderone CA, Gaudette GR, Bukhari EA, Levitsky S. Does cardiopulmonary bypass alone elicit myoprotective preconditioning? Circulation. 1995;92:1447–51.